SB1129 EnrolledLRB099 05307 MRW 25342 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 102, 204, 401, and 402 as follows:
 
6    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
7    Sec. 102. Definitions. As used in this Act, unless the
8context otherwise requires:
9    (a) "Addict" means any person who habitually uses any drug,
10chemical, substance or dangerous drug other than alcohol so as
11to endanger the public morals, health, safety or welfare or who
12is so far addicted to the use of a dangerous drug or controlled
13substance other than alcohol as to have lost the power of self
14control with reference to his or her addiction.
15    (b) "Administer" means the direct application of a
16controlled substance, whether by injection, inhalation,
17ingestion, or any other means, to the body of a patient,
18research subject, or animal (as defined by the Humane
19Euthanasia in Animal Shelters Act) by:
20        (1) a practitioner (or, in his or her presence, by his
21    or her authorized agent),
22        (2) the patient or research subject pursuant to an
23    order, or

 

 

SB1129 Enrolled- 2 -LRB099 05307 MRW 25342 b

1        (3) a euthanasia technician as defined by the Humane
2    Euthanasia in Animal Shelters Act.
3    (c) "Agent" means an authorized person who acts on behalf
4of or at the direction of a manufacturer, distributor,
5dispenser, prescriber, or practitioner. It does not include a
6common or contract carrier, public warehouseman or employee of
7the carrier or warehouseman.
8    (c-1) "Anabolic Steroids" means any drug or hormonal
9substance, chemically and pharmacologically related to
10testosterone (other than estrogens, progestins,
11corticosteroids, and dehydroepiandrosterone), and includes:
12    (i) 3[beta],17-dihydroxy-5a-androstane, 
13    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
14    (iii) 5[alpha]-androstan-3,17-dione, 
15    (iv) 1-androstenediol (3[beta], 
16        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
17    (v) 1-androstenediol (3[alpha], 
18        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
19    (vi) 4-androstenediol  
20        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
21    (vii) 5-androstenediol  
22        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
23    (viii) 1-androstenedione  
24        ([5alpha]-androst-1-en-3,17-dione), 
25    (ix) 4-androstenedione  
26        (androst-4-en-3,17-dione), 

 

 

SB1129 Enrolled- 3 -LRB099 05307 MRW 25342 b

1    (x) 5-androstenedione  
2        (androst-5-en-3,17-dione), 
3    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
4        hydroxyandrost-4-en-3-one), 
5    (xii) boldenone (17[beta]-hydroxyandrost- 
6        1,4,-diene-3-one), 
7    (xiii) boldione (androsta-1,4- 
8        diene-3,17-dione), 
9    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
10        [beta]-hydroxyandrost-4-en-3-one), 
11    (xv) clostebol (4-chloro-17[beta]- 
12        hydroxyandrost-4-en-3-one), 
13    (xvi) dehydrochloromethyltestosterone (4-chloro- 
14        17[beta]-hydroxy-17[alpha]-methyl- 
15        androst-1,4-dien-3-one), 
16    (xvii) desoxymethyltestosterone 
17    (17[alpha]-methyl-5[alpha] 
18        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
19    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
20        '1-testosterone') (17[beta]-hydroxy- 
21        5[alpha]-androst-1-en-3-one), 
22    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
23        androstan-3-one), 
24    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
25        5[alpha]-androstan-3-one), 
26    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 

 

 

SB1129 Enrolled- 4 -LRB099 05307 MRW 25342 b

1        hydroxyestr-4-ene), 
2    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
3        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
4    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
5        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
6    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
7        hydroxyandrostano[2,3-c]-furazan), 
8    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) 
9    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
10        androst-4-en-3-one), 
11    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
12        dihydroxy-estr-4-en-3-one), 
13    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
14        hydroxy-5-androstan-3-one), 
15    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
16        [5a]-androstan-3-one), 
17    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
18        hydroxyandrost-1,4-dien-3-one), 
19    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
20        dihydroxyandrost-5-ene), 
21    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
22        5[alpha]-androst-1-en-3-one), 
23    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
24        dihydroxy-5a-androstane), 
25    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
26        -5a-androstane), 

 

 

SB1129 Enrolled- 5 -LRB099 05307 MRW 25342 b

1    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
2        dihydroxyandrost-4-ene), 
3    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
4        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
5    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
6        hydroxyestra-4,9(10)-dien-3-one), 
7    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
8        hydroxyestra-4,9-11-trien-3-one), 
9    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
10        hydroxyandrost-4-en-3-one), 
11    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
12        hydroxyestr-4-en-3-one), 
13    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
14        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
15        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
16        1-testosterone'), 
17    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
18    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
19        dihydroxyestr-4-ene), 
20    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
21        dihydroxyestr-4-ene), 
22    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
23        dihydroxyestr-5-ene), 
24    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
25        dihydroxyestr-5-ene), 
26    (xlvii) 19-nor-4,9(10)-androstadienedione  

 

 

SB1129 Enrolled- 6 -LRB099 05307 MRW 25342 b

1        (estra-4,9(10)-diene-3,17-dione), 
2    (xlviii) 19-nor-4-androstenedione (estr-4- 
3        en-3,17-dione), 
4    (xlix) 19-nor-5-androstenedione (estr-5- 
5        en-3,17-dione), 
6    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
7        hydroxygon-4-en-3-one), 
8    (li) norclostebol (4-chloro-17[beta]- 
9        hydroxyestr-4-en-3-one), 
10    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
11        hydroxyestr-4-en-3-one), 
12    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
13        hydroxyestr-4-en-3-one), 
14    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
15        2-oxa-5[alpha]-androstan-3-one), 
16    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
17        dihydroxyandrost-4-en-3-one), 
18    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
19        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
20    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
21        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
22    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
23        (5[alpha]-androst-1-en-3-one), 
24    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
25        secoandrosta-1,4-dien-17-oic 
26        acid lactone), 

 

 

SB1129 Enrolled- 7 -LRB099 05307 MRW 25342 b

1    (lx) testosterone (17[beta]-hydroxyandrost- 
2        4-en-3-one), 
3    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
4        diethyl-17[beta]-hydroxygon- 
5        4,9,11-trien-3-one), 
6    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
7        11-trien-3-one). 
8    Any person who is otherwise lawfully in possession of an
9anabolic steroid, or who otherwise lawfully manufactures,
10distributes, dispenses, delivers, or possesses with intent to
11deliver an anabolic steroid, which anabolic steroid is
12expressly intended for and lawfully allowed to be administered
13through implants to livestock or other nonhuman species, and
14which is approved by the Secretary of Health and Human Services
15for such administration, and which the person intends to
16administer or have administered through such implants, shall
17not be considered to be in unauthorized possession or to
18unlawfully manufacture, distribute, dispense, deliver, or
19possess with intent to deliver such anabolic steroid for
20purposes of this Act.
21    (d) "Administration" means the Drug Enforcement
22Administration, United States Department of Justice, or its
23successor agency.
24    (d-5) "Clinical Director, Prescription Monitoring Program"
25means a Department of Human Services administrative employee
26licensed to either prescribe or dispense controlled substances

 

 

SB1129 Enrolled- 8 -LRB099 05307 MRW 25342 b

1who shall run the clinical aspects of the Department of Human
2Services Prescription Monitoring Program and its Prescription
3Information Library.
4    (d-10) "Compounding" means the preparation and mixing of
5components, excluding flavorings, (1) as the result of a
6prescriber's prescription drug order or initiative based on the
7prescriber-patient-pharmacist relationship in the course of
8professional practice or (2) for the purpose of, or incident
9to, research, teaching, or chemical analysis and not for sale
10or dispensing. "Compounding" includes the preparation of drugs
11or devices in anticipation of receiving prescription drug
12orders based on routine, regularly observed dispensing
13patterns. Commercially available products may be compounded
14for dispensing to individual patients only if both of the
15following conditions are met: (i) the commercial product is not
16reasonably available from normal distribution channels in a
17timely manner to meet the patient's needs and (ii) the
18prescribing practitioner has requested that the drug be
19compounded.
20    (e) "Control" means to add a drug or other substance, or
21immediate precursor, to a Schedule whether by transfer from
22another Schedule or otherwise.
23    (f) "Controlled Substance" means (i) a drug, substance, or
24immediate precursor, or synthetic drug in the Schedules of
25Article II of this Act or (ii) a drug or other substance, or
26immediate precursor, designated as a controlled substance by

 

 

SB1129 Enrolled- 9 -LRB099 05307 MRW 25342 b

1the Department through administrative rule. The term does not
2include distilled spirits, wine, malt beverages, or tobacco, as
3those terms are defined or used in the Liquor Control Act of
41934 and the Tobacco Products Tax Act of 1995.
5    (f-5) "Controlled substance analog" means a substance:
6        (1) the chemical structure of which is substantially
7    similar to the chemical structure of a controlled substance
8    in Schedule I or II;
9        (2) which has a stimulant, depressant, or
10    hallucinogenic effect on the central nervous system that is
11    substantially similar to or greater than the stimulant,
12    depressant, or hallucinogenic effect on the central
13    nervous system of a controlled substance in Schedule I or
14    II; or
15        (3) with respect to a particular person, which such
16    person represents or intends to have a stimulant,
17    depressant, or hallucinogenic effect on the central
18    nervous system that is substantially similar to or greater
19    than the stimulant, depressant, or hallucinogenic effect
20    on the central nervous system of a controlled substance in
21    Schedule I or II.
22    (g) "Counterfeit substance" means a controlled substance,
23which, or the container or labeling of which, without
24authorization bears the trademark, trade name, or other
25identifying mark, imprint, number or device, or any likeness
26thereof, of a manufacturer, distributor, or dispenser other

 

 

SB1129 Enrolled- 10 -LRB099 05307 MRW 25342 b

1than the person who in fact manufactured, distributed, or
2dispensed the substance.
3    (h) "Deliver" or "delivery" means the actual, constructive
4or attempted transfer of possession of a controlled substance,
5with or without consideration, whether or not there is an
6agency relationship.
7    (i) "Department" means the Illinois Department of Human
8Services (as successor to the Department of Alcoholism and
9Substance Abuse) or its successor agency.
10    (j) (Blank).
11    (k) "Department of Corrections" means the Department of
12Corrections of the State of Illinois or its successor agency.
13    (l) "Department of Financial and Professional Regulation"
14means the Department of Financial and Professional Regulation
15of the State of Illinois or its successor agency.
16    (m) "Depressant" means any drug that (i) causes an overall
17depression of central nervous system functions, (ii) causes
18impaired consciousness and awareness, and (iii) can be
19habit-forming or lead to a substance abuse problem, including
20but not limited to alcohol, cannabis and its active principles
21and their analogs, benzodiazepines and their analogs,
22barbiturates and their analogs, opioids (natural and
23synthetic) and their analogs, and chloral hydrate and similar
24sedative hypnotics.
25    (n) (Blank).
26    (o) "Director" means the Director of the Illinois State

 

 

SB1129 Enrolled- 11 -LRB099 05307 MRW 25342 b

1Police or his or her designated agents.
2    (p) "Dispense" means to deliver a controlled substance to
3an ultimate user or research subject by or pursuant to the
4lawful order of a prescriber, including the prescribing,
5administering, packaging, labeling, or compounding necessary
6to prepare the substance for that delivery.
7    (q) "Dispenser" means a practitioner who dispenses.
8    (r) "Distribute" means to deliver, other than by
9administering or dispensing, a controlled substance.
10    (s) "Distributor" means a person who distributes.
11    (t) "Drug" means (1) substances recognized as drugs in the
12official United States Pharmacopoeia, Official Homeopathic
13Pharmacopoeia of the United States, or official National
14Formulary, or any supplement to any of them; (2) substances
15intended for use in diagnosis, cure, mitigation, treatment, or
16prevention of disease in man or animals; (3) substances (other
17than food) intended to affect the structure of any function of
18the body of man or animals and (4) substances intended for use
19as a component of any article specified in clause (1), (2), or
20(3) of this subsection. It does not include devices or their
21components, parts, or accessories.
22    (t-5) "Euthanasia agency" means an entity certified by the
23Department of Financial and Professional Regulation for the
24purpose of animal euthanasia that holds an animal control
25facility license or animal shelter license under the Animal
26Welfare Act. A euthanasia agency is authorized to purchase,

 

 

SB1129 Enrolled- 12 -LRB099 05307 MRW 25342 b

1store, possess, and utilize Schedule II nonnarcotic and
2Schedule III nonnarcotic drugs for the sole purpose of animal
3euthanasia.
4    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
5substances (nonnarcotic controlled substances) that are used
6by a euthanasia agency for the purpose of animal euthanasia.
7    (u) "Good faith" means the prescribing or dispensing of a
8controlled substance by a practitioner in the regular course of
9professional treatment to or for any person who is under his or
10her treatment for a pathology or condition other than that
11individual's physical or psychological dependence upon or
12addiction to a controlled substance, except as provided herein:
13and application of the term to a pharmacist shall mean the
14dispensing of a controlled substance pursuant to the
15prescriber's order which in the professional judgment of the
16pharmacist is lawful. The pharmacist shall be guided by
17accepted professional standards including, but not limited to
18the following, in making the judgment:
19        (1) lack of consistency of prescriber-patient
20    relationship,
21        (2) frequency of prescriptions for same drug by one
22    prescriber for large numbers of patients,
23        (3) quantities beyond those normally prescribed,
24        (4) unusual dosages (recognizing that there may be
25    clinical circumstances where more or less than the usual
26    dose may be used legitimately),

 

 

SB1129 Enrolled- 13 -LRB099 05307 MRW 25342 b

1        (5) unusual geographic distances between patient,
2    pharmacist and prescriber,
3        (6) consistent prescribing of habit-forming drugs.
4    (u-0.5) "Hallucinogen" means a drug that causes markedly
5altered sensory perception leading to hallucinations of any
6type.
7    (u-1) "Home infusion services" means services provided by a
8pharmacy in compounding solutions for direct administration to
9a patient in a private residence, long-term care facility, or
10hospice setting by means of parenteral, intravenous,
11intramuscular, subcutaneous, or intraspinal infusion.
12    (u-5) "Illinois State Police" means the State Police of the
13State of Illinois, or its successor agency.
14    (v) "Immediate precursor" means a substance:
15        (1) which the Department has found to be and by rule
16    designated as being a principal compound used, or produced
17    primarily for use, in the manufacture of a controlled
18    substance;
19        (2) which is an immediate chemical intermediary used or
20    likely to be used in the manufacture of such controlled
21    substance; and
22        (3) the control of which is necessary to prevent,
23    curtail or limit the manufacture of such controlled
24    substance.
25    (w) "Instructional activities" means the acts of teaching,
26educating or instructing by practitioners using controlled

 

 

SB1129 Enrolled- 14 -LRB099 05307 MRW 25342 b

1substances within educational facilities approved by the State
2Board of Education or its successor agency.
3    (x) "Local authorities" means a duly organized State,
4County or Municipal peace unit or police force.
5    (y) "Look-alike substance" means a substance, other than a
6controlled substance which (1) by overall dosage unit
7appearance, including shape, color, size, markings or lack
8thereof, taste, consistency, or any other identifying physical
9characteristic of the substance, would lead a reasonable person
10to believe that the substance is a controlled substance, or (2)
11is expressly or impliedly represented to be a controlled
12substance or is distributed under circumstances which would
13lead a reasonable person to believe that the substance is a
14controlled substance. For the purpose of determining whether
15the representations made or the circumstances of the
16distribution would lead a reasonable person to believe the
17substance to be a controlled substance under this clause (2) of
18subsection (y), the court or other authority may consider the
19following factors in addition to any other factor that may be
20relevant:
21        (a) statements made by the owner or person in control
22    of the substance concerning its nature, use or effect;
23        (b) statements made to the buyer or recipient that the
24    substance may be resold for profit;
25        (c) whether the substance is packaged in a manner
26    normally used for the illegal distribution of controlled

 

 

SB1129 Enrolled- 15 -LRB099 05307 MRW 25342 b

1    substances;
2        (d) whether the distribution or attempted distribution
3    included an exchange of or demand for money or other
4    property as consideration, and whether the amount of the
5    consideration was substantially greater than the
6    reasonable retail market value of the substance.
7    Clause (1) of this subsection (y) shall not apply to a
8noncontrolled substance in its finished dosage form that was
9initially introduced into commerce prior to the initial
10introduction into commerce of a controlled substance in its
11finished dosage form which it may substantially resemble.
12    Nothing in this subsection (y) prohibits the dispensing or
13distributing of noncontrolled substances by persons authorized
14to dispense and distribute controlled substances under this
15Act, provided that such action would be deemed to be carried
16out in good faith under subsection (u) if the substances
17involved were controlled substances.
18    Nothing in this subsection (y) or in this Act prohibits the
19manufacture, preparation, propagation, compounding,
20processing, packaging, advertising or distribution of a drug or
21drugs by any person registered pursuant to Section 510 of the
22Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
23    (y-1) "Mail-order pharmacy" means a pharmacy that is
24located in a state of the United States that delivers,
25dispenses or distributes, through the United States Postal
26Service or other common carrier, to Illinois residents, any

 

 

SB1129 Enrolled- 16 -LRB099 05307 MRW 25342 b

1substance which requires a prescription.
2    (z) "Manufacture" means the production, preparation,
3propagation, compounding, conversion or processing of a
4controlled substance other than methamphetamine, either
5directly or indirectly, by extraction from substances of
6natural origin, or independently by means of chemical
7synthesis, or by a combination of extraction and chemical
8synthesis, and includes any packaging or repackaging of the
9substance or labeling of its container, except that this term
10does not include:
11        (1) by an ultimate user, the preparation or compounding
12    of a controlled substance for his or her own use; or
13        (2) by a practitioner, or his or her authorized agent
14    under his or her supervision, the preparation,
15    compounding, packaging, or labeling of a controlled
16    substance:
17            (a) as an incident to his or her administering or
18        dispensing of a controlled substance in the course of
19        his or her professional practice; or
20            (b) as an incident to lawful research, teaching or
21        chemical analysis and not for sale.
22    (z-1) (Blank).
23    (z-5) "Medication shopping" means the conduct prohibited
24under subsection (a) of Section 314.5 of this Act.
25    (z-10) "Mid-level practitioner" means (i) a physician
26assistant who has been delegated authority to prescribe through

 

 

SB1129 Enrolled- 17 -LRB099 05307 MRW 25342 b

1a written delegation of authority by a physician licensed to
2practice medicine in all of its branches, in accordance with
3Section 7.5 of the Physician Assistant Practice Act of 1987,
4(ii) an advanced practice nurse who has been delegated
5authority to prescribe through a written delegation of
6authority by a physician licensed to practice medicine in all
7of its branches or by a podiatric physician, in accordance with
8Section 65-40 of the Nurse Practice Act, (iii) an animal
9euthanasia agency, or (iv) a prescribing psychologist.
10    (aa) "Narcotic drug" means any of the following, whether
11produced directly or indirectly by extraction from substances
12of vegetable origin, or independently by means of chemical
13synthesis, or by a combination of extraction and chemical
14synthesis:
15        (1) opium, opiates, derivatives of opium and opiates,
16    including their isomers, esters, ethers, salts, and salts
17    of isomers, esters, and ethers, whenever the existence of
18    such isomers, esters, ethers, and salts is possible within
19    the specific chemical designation; however the term
20    "narcotic drug" does not include the isoquinoline
21    alkaloids of opium;
22        (2) (blank);
23        (3) opium poppy and poppy straw;
24        (4) coca leaves, except coca leaves and extracts of
25    coca leaves from which substantially all of the cocaine and
26    ecgonine, and their isomers, derivatives and salts, have

 

 

SB1129 Enrolled- 18 -LRB099 05307 MRW 25342 b

1    been removed;
2        (5) cocaine, its salts, optical and geometric isomers,
3    and salts of isomers;
4        (6) ecgonine, its derivatives, their salts, isomers,
5    and salts of isomers;
6        (7) any compound, mixture, or preparation which
7    contains any quantity of any of the substances referred to
8    in subparagraphs (1) through (6).
9    (bb) "Nurse" means a registered nurse licensed under the
10Nurse Practice Act.
11    (cc) (Blank).
12    (dd) "Opiate" means any substance having an addiction
13forming or addiction sustaining liability similar to morphine
14or being capable of conversion into a drug having addiction
15forming or addiction sustaining liability.
16    (ee) "Opium poppy" means the plant of the species Papaver
17somniferum L., except its seeds.
18    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
19solution or other liquid form of medication intended for
20administration by mouth, but the term does not include a form
21of medication intended for buccal, sublingual, or transmucosal
22administration.
23    (ff) "Parole and Pardon Board" means the Parole and Pardon
24Board of the State of Illinois or its successor agency.
25    (gg) "Person" means any individual, corporation,
26mail-order pharmacy, government or governmental subdivision or

 

 

SB1129 Enrolled- 19 -LRB099 05307 MRW 25342 b

1agency, business trust, estate, trust, partnership or
2association, or any other entity.
3    (hh) "Pharmacist" means any person who holds a license or
4certificate of registration as a registered pharmacist, a local
5registered pharmacist or a registered assistant pharmacist
6under the Pharmacy Practice Act.
7    (ii) "Pharmacy" means any store, ship or other place in
8which pharmacy is authorized to be practiced under the Pharmacy
9Practice Act.
10    (ii-5) "Pharmacy shopping" means the conduct prohibited
11under subsection (b) of Section 314.5 of this Act.
12    (ii-10) "Physician" (except when the context otherwise
13requires) means a person licensed to practice medicine in all
14of its branches.
15    (jj) "Poppy straw" means all parts, except the seeds, of
16the opium poppy, after mowing.
17    (kk) "Practitioner" means a physician licensed to practice
18medicine in all its branches, dentist, optometrist, podiatric
19physician, veterinarian, scientific investigator, pharmacist,
20physician assistant, advanced practice nurse, licensed
21practical nurse, registered nurse, hospital, laboratory, or
22pharmacy, or other person licensed, registered, or otherwise
23lawfully permitted by the United States or this State to
24distribute, dispense, conduct research with respect to,
25administer or use in teaching or chemical analysis, a
26controlled substance in the course of professional practice or

 

 

SB1129 Enrolled- 20 -LRB099 05307 MRW 25342 b

1research.
2    (ll) "Pre-printed prescription" means a written
3prescription upon which the designated drug has been indicated
4prior to the time of issuance; the term does not mean a written
5prescription that is individually generated by machine or
6computer in the prescriber's office.
7    (mm) "Prescriber" means a physician licensed to practice
8medicine in all its branches, dentist, optometrist,
9prescribing psychologist licensed under Section 4.2 of the
10Clinical Psychologist Licensing Act with prescriptive
11authority delegated under Section 4.3 of the Clinical
12Psychologist Licensing Act, podiatric physician, or
13veterinarian who issues a prescription, a physician assistant
14who issues a prescription for a controlled substance in
15accordance with Section 303.05, a written delegation, and a
16written supervision agreement required under Section 7.5 of the
17Physician Assistant Practice Act of 1987, or an advanced
18practice nurse with prescriptive authority delegated under
19Section 65-40 of the Nurse Practice Act and in accordance with
20Section 303.05, a written delegation, and a written
21collaborative agreement under Section 65-35 of the Nurse
22Practice Act.
23    (nn) "Prescription" means a written, facsimile, or oral
24order, or an electronic order that complies with applicable
25federal requirements, of a physician licensed to practice
26medicine in all its branches, dentist, podiatric physician or

 

 

SB1129 Enrolled- 21 -LRB099 05307 MRW 25342 b

1veterinarian for any controlled substance, of an optometrist
2for a Schedule II, III, IV, or V controlled substance in
3accordance with Section 15.1 of the Illinois Optometric
4Practice Act of 1987, of a prescribing psychologist licensed
5under Section 4.2 of the Clinical Psychologist Licensing Act
6with prescriptive authority delegated under Section 4.3 of the
7Clinical Psychologist Licensing Act, of a physician assistant
8for a controlled substance in accordance with Section 303.05, a
9written delegation, and a written supervision agreement
10required under Section 7.5 of the Physician Assistant Practice
11Act of 1987, or of an advanced practice nurse with prescriptive
12authority delegated under Section 65-40 of the Nurse Practice
13Act who issues a prescription for a controlled substance in
14accordance with Section 303.05, a written delegation, and a
15written collaborative agreement under Section 65-35 of the
16Nurse Practice Act when required by law.
17    (nn-5) "Prescription Information Library" (PIL) means an
18electronic library that contains reported controlled substance
19data.
20    (nn-10) "Prescription Monitoring Program" (PMP) means the
21entity that collects, tracks, and stores reported data on
22controlled substances and select drugs pursuant to Section 316.
23    (oo) "Production" or "produce" means manufacture,
24planting, cultivating, growing, or harvesting of a controlled
25substance other than methamphetamine.
26    (pp) "Registrant" means every person who is required to

 

 

SB1129 Enrolled- 22 -LRB099 05307 MRW 25342 b

1register under Section 302 of this Act.
2    (qq) "Registry number" means the number assigned to each
3person authorized to handle controlled substances under the
4laws of the United States and of this State.
5    (qq-5) "Secretary" means, as the context requires, either
6the Secretary of the Department or the Secretary of the
7Department of Financial and Professional Regulation, and the
8Secretary's designated agents.
9    (rr) "State" includes the State of Illinois and any state,
10district, commonwealth, territory, insular possession thereof,
11and any area subject to the legal authority of the United
12States of America.
13    (rr-5) "Stimulant" means any drug that (i) causes an
14overall excitation of central nervous system functions, (ii)
15causes impaired consciousness and awareness, and (iii) can be
16habit-forming or lead to a substance abuse problem, including
17but not limited to amphetamines and their analogs,
18methylphenidate and its analogs, cocaine, and phencyclidine
19and its analogs.
20    (ss) "Ultimate user" means a person who lawfully possesses
21a controlled substance for his or her own use or for the use of
22a member of his or her household or for administering to an
23animal owned by him or her or by a member of his or her
24household.
25(Source: P.A. 97-334, eff. 1-1-12; 98-214, eff. 8-9-13; 98-668,
26eff. 6-25-14; 98-756, eff. 7-16-14; 98-1111, eff. 8-26-14;

 

 

SB1129 Enrolled- 23 -LRB099 05307 MRW 25342 b

1revised 10-1-14.)
 
2    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
3    Sec. 204. (a) The controlled substances listed in this
4Section are included in Schedule I.
5    (b) Unless specifically excepted or unless listed in
6another schedule, any of the following opiates, including their
7isomers, esters, ethers, salts, and salts of isomers, esters,
8and ethers, whenever the existence of such isomers, esters,
9ethers and salts is possible within the specific chemical
10designation:
11        (1) Acetylmethadol;
12        (1.1) Acetyl-alpha-methylfentanyl
13    (N-[1-(1-methyl-2-phenethyl)-
14    4-piperidinyl]-N-phenylacetamide);
15        (2) Allylprodine;
16        (3) Alphacetylmethadol, except
17    levo-alphacetylmethadol (also known as levo-alpha-
18    acetylmethadol, levomethadyl acetate, or LAAM);
19        (4) Alphameprodine;
20        (5) Alphamethadol;
21        (6) Alpha-methylfentanyl
22    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
23    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
24    propanilido) piperidine;
25        (6.1) Alpha-methylthiofentanyl

 

 

SB1129 Enrolled- 24 -LRB099 05307 MRW 25342 b

1    (N-[1-methyl-2-(2-thienyl)ethyl-
2    4-piperidinyl]-N-phenylpropanamide);
3        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
4        (7.1) PEPAP
5    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
6        (8) Benzethidine;
7        (9) Betacetylmethadol;
8        (9.1) Beta-hydroxyfentanyl
9    (N-[1-(2-hydroxy-2-phenethyl)-
10    4-piperidinyl]-N-phenylpropanamide);
11        (10) Betameprodine;
12        (11) Betamethadol;
13        (12) Betaprodine;
14        (13) Clonitazene;
15        (14) Dextromoramide;
16        (15) Diampromide;
17        (16) Diethylthiambutene;
18        (17) Difenoxin;
19        (18) Dimenoxadol;
20        (19) Dimepheptanol;
21        (20) Dimethylthiambutene;
22        (21) Dioxaphetylbutyrate;
23        (22) Dipipanone;
24        (23) Ethylmethylthiambutene;
25        (24) Etonitazene;
26        (25) Etoxeridine;

 

 

SB1129 Enrolled- 25 -LRB099 05307 MRW 25342 b

1        (26) Furethidine;
2        (27) Hydroxpethidine;
3        (28) Ketobemidone;
4        (29) Levomoramide;
5        (30) Levophenacylmorphan;
6        (31) 3-Methylfentanyl
7    (N-[3-methyl-1-(2-phenylethyl)-
8    4-piperidyl]-N-phenylpropanamide);
9        (31.1) 3-Methylthiofentanyl
10    (N-[(3-methyl-1-(2-thienyl)ethyl-
11    4-piperidinyl]-N-phenylpropanamide);
12        (32) Morpheridine;
13        (33) Noracymethadol;
14        (34) Norlevorphanol;
15        (35) Normethadone;
16        (36) Norpipanone;
17        (36.1) Para-fluorofentanyl
18    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
19    4-piperidinyl]propanamide);
20        (37) Phenadoxone;
21        (38) Phenampromide;
22        (39) Phenomorphan;
23        (40) Phenoperidine;
24        (41) Piritramide;
25        (42) Proheptazine;
26        (43) Properidine;

 

 

SB1129 Enrolled- 26 -LRB099 05307 MRW 25342 b

1        (44) Propiram;
2        (45) Racemoramide;
3        (45.1) Thiofentanyl
4    (N-phenyl-N-[1-(2-thienyl)ethyl-
5    4-piperidinyl]-propanamide);
6        (46) Tilidine;
7        (47) Trimeperidine;
8        (48) Beta-hydroxy-3-methylfentanyl (other name:
9    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
10    N-phenylpropanamide).
11    (c) Unless specifically excepted or unless listed in
12another schedule, any of the following opium derivatives, its
13salts, isomers and salts of isomers, whenever the existence of
14such salts, isomers and salts of isomers is possible within the
15specific chemical designation:
16        (1) Acetorphine;
17        (2) Acetyldihydrocodeine;
18        (3) Benzylmorphine;
19        (4) Codeine methylbromide;
20        (5) Codeine-N-Oxide;
21        (6) Cyprenorphine;
22        (7) Desomorphine;
23        (8) Diacetyldihydromorphine (Dihydroheroin);
24        (9) Dihydromorphine;
25        (10) Drotebanol;
26        (11) Etorphine (except hydrochloride salt);

 

 

SB1129 Enrolled- 27 -LRB099 05307 MRW 25342 b

1        (12) Heroin;
2        (13) Hydromorphinol;
3        (14) Methyldesorphine;
4        (15) Methyldihydromorphine;
5        (16) Morphine methylbromide;
6        (17) Morphine methylsulfonate;
7        (18) Morphine-N-Oxide;
8        (19) Myrophine;
9        (20) Nicocodeine;
10        (21) Nicomorphine;
11        (22) Normorphine;
12        (23) Pholcodine;
13        (24) Thebacon.
14    (d) Unless specifically excepted or unless listed in
15another schedule, any material, compound, mixture, or
16preparation which contains any quantity of the following
17hallucinogenic substances, or which contains any of its salts,
18isomers and salts of isomers, whenever the existence of such
19salts, isomers, and salts of isomers is possible within the
20specific chemical designation (for the purposes of this
21paragraph only, the term "isomer" includes the optical,
22position and geometric isomers):
23        (1) 3,4-methylenedioxyamphetamine
24    (alpha-methyl,3,4-methylenedioxyphenethylamine,
25    methylenedioxyamphetamine, MDA);
26        (1.1) Alpha-ethyltryptamine

 

 

SB1129 Enrolled- 28 -LRB099 05307 MRW 25342 b

1    (some trade or other names: etryptamine;
2    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
3    3-(2-aminobutyl)indole; a-ET; and AET);
4        (2) 3,4-methylenedioxymethamphetamine (MDMA);
5        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
6    (also known as: N-ethyl-alpha-methyl-
7    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
8    and MDEA);
9        (2.2) N-Benzylpiperazine (BZP);
10        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
11        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
12        (4) 3,4,5-trimethoxyamphetamine (TMA);
13        (5) (Blank);
14        (6) Diethyltryptamine (DET);
15        (7) Dimethyltryptamine (DMT);
16        (7.1) 5-Methoxy-diallyltryptamine;
17        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
18        (9) Ibogaine  (some trade and other names:
19    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
20    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
21    indole; Tabernanthe iboga);
22        (10) Lysergic acid diethylamide;
23        (10.1) Salvinorin A;
24        (10.5) Salvia divinorum (meaning all parts of the plant
25    presently classified botanically as Salvia divinorum,
26    whether growing or not, the seeds thereof, any extract from

 

 

SB1129 Enrolled- 29 -LRB099 05307 MRW 25342 b

1    any part of that plant, and every compound, manufacture,
2    salts, isomers, and salts of isomers whenever the existence
3    of such salts, isomers, and salts of isomers is possible
4    within the specific chemical designation, derivative,
5    mixture, or preparation of that plant, its seeds or
6    extracts);
7        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
8        (12) Peyote (meaning all parts of the plant presently
9    classified botanically as Lophophora williamsii Lemaire,
10    whether growing or not, the seeds thereof, any extract from
11    any part of that plant, and every compound, manufacture,
12    salts, derivative, mixture, or preparation of that plant,
13    its seeds or extracts);
14        (13) N-ethyl-3-piperidyl benzilate (JB 318);
15        (14) N-methyl-3-piperidyl benzilate;
16        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
17    (also known as N-hydroxy-alpha-methyl-
18    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
19        (15) Parahexyl; some trade or other names:
20    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
21    dibenzo (b,d) pyran; Synhexyl;
22        (16) Psilocybin;
23        (17) Psilocyn;
24        (18) Alpha-methyltryptamine (AMT);
25        (19) 2,5-dimethoxyamphetamine
26    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

 

 

SB1129 Enrolled- 30 -LRB099 05307 MRW 25342 b

1        (20) 4-bromo-2,5-dimethoxyamphetamine
2    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
3    4-bromo-2,5-DMA);
4        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
5    Some trade or other names: 2-(4-bromo-
6    2,5-dimethoxyphenyl)-1-aminoethane;
7    alpha-desmethyl DOB, 2CB, Nexus;
8        (21) 4-methoxyamphetamine
9    (4-methoxy-alpha-methylphenethylamine;
10    paramethoxyamphetamine; PMA);
11        (22) (Blank);
12        (23) Ethylamine analog of phencyclidine.
13    Some trade or other names:
14    N-ethyl-1-phenylcyclohexylamine,
15    (1-phenylcyclohexyl) ethylamine,
16    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
17        (24) Pyrrolidine analog of phencyclidine. Some trade
18    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
19    PHP;
20        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
21        (26) 2,5-dimethoxy-4-ethylamphetamine
22    (another name: DOET);
23        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
24    (another name: TCPy);
25        (28) (Blank);
26        (29) Thiophene analog of phencyclidine (some trade

 

 

SB1129 Enrolled- 31 -LRB099 05307 MRW 25342 b

1    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
2    2-thienyl analog of phencyclidine; TPCP; TCP);
3        (30) Bufotenine (some trade or other names:
4    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
5    3-(2-dimethylaminoethyl)-5-indolol;
6    5-hydroxy-N,N-dimethyltryptamine;
7    N,N-dimethylserotonin; mappine);
8        (31)  1-Pentyl-3-(1-naphthoyl)indole 
9    Some trade or other names: JWH-018; 
10        (32) 1-Butyl-3-(1-naphthoyl)indole 
11    Some trade or other names: JWH-073;  
12        (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- 
13    (2-iodophenyl)methanone 
14    Some trade or other names: AM-694;
15        (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
16    (2-methyloctan-2-yl)phenol 
17    Some trade or other names: CP 47,497 
18    and its C6, C8 and C9 homologs;
19        (34.5)  2-[(1R,3S)-3-hydroxycyclohexyl]-5- 
20    (2-methyloctan-2-yl)phenol), where side chain n=5;  
21    and homologues where side chain n=4, 6, or 7;  Some  
22    trade or other names: CP 47,497; 
23        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
24    (2-methyloctan-2-yl)-6a,7, 
25    10,10a-tetrahydrobenzo[c]chromen-1-ol
26    Some trade or other names: HU-210; 

 

 

SB1129 Enrolled- 32 -LRB099 05307 MRW 25342 b

1        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
2    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
3    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
4    salts, and salts of isomers; Some trade or other  
5    names: HU-210, Dexanabinol; 
6        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
7    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
8    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
9    Some trade or other names: HU-211;
10        (37) (2-methyl-1-propyl-1H-indol-
11    3-yl)-1-naphthalenyl-methanone 
12    Some trade or other names: JWH-015;
13        (38) 4-methoxynaphthalen-1-yl-
14    (1-pentylindol-3-yl)methanone 
15    Some trade or other names: JWH-081;
16        (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
17    Some trade or other names: JWH-122;
18        (40) 2-(2-methylphenyl)-1-(1-pentyl-
19    1H-indol-3-yl)-ethanone 
20    Some trade or other names: JWH-251;
21        (41) 1-(2-cyclohexylethyl)-3- 
22    (2-methoxyphenylacetyl)indole 
23    Some trade or other names: RCS-8, BTW-8 and SR-18; 
24        (42)  Any compound structurally derived from 
25    3-(1-naphthoyl)indole or 1H-indol-3-yl- 
26    (1-naphthyl)methane by substitution at the 

 

 

SB1129 Enrolled- 33 -LRB099 05307 MRW 25342 b

1    nitrogen atom of the indole ring by alkyl, haloalkyl, 
2    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
3    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
4    or 2-(4-morpholinyl)ethyl whether or not further 
5    substituted in the indole ring to any extent, whether 
6    or not substituted in the naphthyl ring to any extent.
7    Examples of this structural class include, but are
8    not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
9    and JWH-185;
10        (43)  Any compound structurally derived from 
11    3-(1-naphthoyl)pyrrole by substitution at the nitrogen 
12    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 
13    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
14    aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
15    or 2-(4-morpholinyl)ethyl, whether or not further 
16    substituted in the pyrrole ring to any extent, whether 
17    or not substituted in the naphthyl ring to any extent.
18    Examples of this structural class include, but are not
19    limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
20    JWH-368
21        (44)  Any compound structurally derived from 
22    1-(1-naphthylmethyl)indene by substitution 
23    at the 3-position of the indene ring by alkyl, haloalkyl, 
24    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
25    halide, alkyl aryl halide, 1-(N-methyl-
26    2-piperidinyl)methyl, or 2-(4-

 

 

SB1129 Enrolled- 34 -LRB099 05307 MRW 25342 b

1    morpholinyl)ethyl whether or not further substituted in
2    the indene ring to any extent, whether or not substituted
3    in the naphthyl ring to any extent. Examples of
4    this structural class include, but are not
5    limited to, JWH-176
6        (45)  Any compound structurally derived from 
7    3-phenylacetylindole by substitution at the 
8    nitrogen atom of the indole ring with alkyl, haloalkyl, 
9    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
10    halide, alkyl aryl halide, 1-(N-methyl-2-
11    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
12    whether or not further substituted in the indole ring
13    to any extent, whether or not substituted in the phenyl
14    ring to any extent. Examples of this structural
15    class include, but are not limited to, JWH-167,
16    JWH-250, JWH-251, and RCS-8
17        (46)  Any compound structurally derived from 
18    2-(3-hydroxycyclohexyl)phenol by substitution 
19    at the 5-position of the phenolic ring by alkyl, 
20    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
21    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
22    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
23    whether or not substituted in the cyclohexyl ring to any
24    extent. Examples of this structural class
25    include, but are not limited to, CP 47,
26    497 and its C8 homologue (cannabicyclohexanol)

 

 

SB1129 Enrolled- 35 -LRB099 05307 MRW 25342 b

1        (46.1) Benzoylindoles: Any compound 
2    containing a 3-(benzoyl) indole structure with 
3    substitution at the nitrogen atom of the 
4    indole ring by an alkyl, haloalkyl, alkenyl, 
5    cycloalkylmethyl, cycloalkylethyl, 
6    1-(N-methyl-2-piperidinyl)methyl, 
7    or 2-(4-morpholinyl)ethyl group 
8    whether or not further substituted 
9    in the indole ring to any extent and 
10    whether or not substituted in the phenyl ring 
11    to any extent. Examples of this structural class 
12    include, but are not limited, to AM-630, 
13    AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; 
14        (47)  3,4-Methylenedioxymethcathinone 
15    Some trade or other names: Methylone; 
16        (48)  3,4-Methyenedioxypyrovalerone 
17    Some trade or other names: MDPV; 
18        (49)  4-Methylmethcathinone 
19    Some trade or other names: Mephedrone; 
20        (50)  4-methoxymethcathinone; 
21        (51)  4-Fluoromethcathinone; 
22        (52)  3-Fluoromethcathinone; 
23        (53)  2,5-Dimethoxy-4-(n)-propylthio- 
24    phenethylamine; 
25        (54)  5-Methoxy-N,N-diisopropyltryptamine; 
26        (55) Pentedrone;  

 

 

SB1129 Enrolled- 36 -LRB099 05307 MRW 25342 b

1        (56)  4-iodo-2,5-dimethoxy-N-((2-methoxy 
2    phenyl)methyl)-benzeneethanamine 
3    (trade or other name: 25I-NBOMe); 
4        (57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl) 
5    methyl]-benzeneethanamine (trade or other name: 
6    25C-NBOMe); 
7        (58)  4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl) 
8    methyl]-benzeneethanamine (trade or other name: 
9    25B-NBOMe); . 
10        (59) 3-cyclopropoylindole with 
11    substitution at the nitrogen atom of the 
12    indole ring by alkyl, haloalkyl, alkenyl, 
13    cycloalkylmethyl, cycloalkylethyl, aryl 
14    halide, alkyl aryl halide, 
15    1-(N-methyl-2-piperidinyl)methyl, or 
16    2-(4-morpholinyl)ethyl, whether or not 
17    further substituted on the indole ring 
18    to any extent, whether or not substituted 
19    on the cyclopropyl ring to any extent: 
20    including but not limited to XLR11, 
21    UR144, FUB-144; 
22        (60) 3-adamantoylindole with 
23    substitution at the nitrogen atom of the 
24    indole ring by alkyl, haloalkyl, alkenyl, 
25    cycloalkylmethyl, cycloalkylethyl, 
26    aryl halide, alkyl aryl halide, 

 

 

SB1129 Enrolled- 37 -LRB099 05307 MRW 25342 b

1    1-(N-methyl-2-piperidinyl)methyl, or 
2    2-(4-morpholinyl)ethyl, whether or not 
3    further substituted on the indole ring to 
4    any extent, whether or not substituted on 
5    the adamantyl ring to any extent: including 
6    but not limited to AB-001; 
7        (61) N-(adamantyl)-indole-3-carboxamide 
8    with substitution at the nitrogen atom of the 
9    indole ring by alkyl, haloalkyl, alkenyl, 
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, 
11    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
12    or 2-(4-morpholinyl)ethyl, whether or not further 
13    substituted on the indole ring to any extent, whether 
14    or not substituted on the adamantyl ring to any 
15    extent: including but not limited to 
16    APICA/2NE-1, STS-135; 
17        (62) N-(adamantyl)-indazole-3-carboxamide 
18    with substitution at a nitrogen atom of the indazole 
19    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
20    cycloalkylethyl, aryl halide, alkyl aryl halide, 
21    1-(N-methyl-2-piperidinyl)methyl, or 
22    2-(4-morpholinyl)ethyl, whether or not further 
23    substituted on the indazole ring to any extent, 
24    whether or not substituted on the adamantyl 
25    ring to any extent: including but not limited 
26    to AKB48, 5F-AKB48; 

 

 

SB1129 Enrolled- 38 -LRB099 05307 MRW 25342 b

1        (63) 1H-indole-3-carboxylic acid 8-quinolinyl 
2    ester with substitution at the nitrogen atom of the 
3    indole ring by alkyl, haloalkyl, alkenyl, 
4    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
5    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
6    2-(4-morpholinyl)ethyl, whether or not further 
7    substituted on the indole ring to any extent, 
8    whether or not substituted on the quinoline ring 
9    to any extent: including but not limited to PB22, 
10    5F-PB22, FUB-PB-22; 
11        (64) 3-(1-naphthoyl)indazole with 
12    substitution at the nitrogen atom of the 
13    indazole ring by alkyl, haloalkyl, 
14    alkenyl, cycloalkylmethyl, cycloalkylethyl, 
15    aryl halide, alkyl aryl halide, 
16    1-(N-methyl-2-piperidinyl)methyl, or 
17    2-(4-morpholinyl)ethyl, whether or not further 
18    substituted on the indazole ring to any extent, 
19    whether or not substituted on the naphthyl ring 
20    to any extent: including but not limited to 
21    THJ-018, THJ-2201; 
22        (65) 2-(1-naphthoyl)benzimidazole with 
23    substitution at the nitrogen atom of the benzimidazole 
24    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
25    cycloalkylethyl, aryl halide, alkyl aryl halide, 
26    1-(N-methyl-2-piperidinyl)methyl, or 

 

 

SB1129 Enrolled- 39 -LRB099 05307 MRW 25342 b

1    2-(4-morpholinyl)ethyl, whether or not further 
2    substituted on the benzimidazole ring to any extent, 
3    whether or not substituted on the naphthyl ring to 
4    any extent: including, but not limited to FUBIMINA; 
5        (66) N-(1-amino-3-methyl-1-oxobutan-2-yl) 
6    -1H-indazole-3-carboxamide with substitution on the 
7    nitrogen atom of the indazole ring by alkyl, 
8    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
9    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
10    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
11    whether or not further substituted on the indazole 
12    ring to any extent: including but not limited to 
13    AB-PINACA, AB-FUBINACA, AB-CHMINACA; 
14        (67) N-(1-amino-3,3-dimethyl-1-oxobutan- 
15    2-yl)-1H-indazole-3-carboxamide with substitution 
16    on the nitrogen atom of the indazole ring by alkyl, 
17    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
18    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
19    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether 
20    or not further substituted on the indazole ring to any 
21    extent: including but not limited to ADB-PINACA, 
22ADB-FUBINACA; 
23        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 
24    1H-indole-3-carboxamide with substitution on the nitrogen 
25    atom of the indole ring by alkyl, haloalkyl, alkenyl, 
26    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 

 

 

SB1129 Enrolled- 40 -LRB099 05307 MRW 25342 b

1    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
2    2-(4-morpholinyl)ethyl, whether or not further 
3    substituted on the indole ring to any extent: 
4    including but not limited to ADBICA, 5F-ADBICA; 
5        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- 
6    1H-indole-3-carboxamide with substitution on the 
7    nitrogen atom of the indole ring by alkyl, haloalkyl, 
8    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
9    halide, alkyl aryl halide, 1-(N-methyl-2- 
10    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
11    whether or not further substituted on the indole 
12    ring to any extent: including but not limited 
13    to ABICA, 5F-ABICA; 
14        (70) Methyl 2-(1H-indazole-3-carboxamido)- 
15    3-methylbutanoate with substitution on the nitrogen 
16    atom of the indazole ring by alkyl, haloalkyl, 
17    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
18    halide, alkyl aryl halide, 1-(N-methyl-2- 
19    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
20    whether or not further substituted on the indazole 
21    ring to any extent: including but not limited to AMB, 
225F-AMB. 
23    (e) Unless specifically excepted or unless listed in
24another schedule, any material, compound, mixture, or
25preparation which contains any quantity of the following
26substances having a depressant effect on the central nervous

 

 

SB1129 Enrolled- 41 -LRB099 05307 MRW 25342 b

1system, including its salts, isomers, and salts of isomers
2whenever the existence of such salts, isomers, and salts of
3isomers is possible within the specific chemical designation:
4        (1) mecloqualone;
5        (2) methaqualone; and
6        (3) gamma hydroxybutyric acid.
7    (f) Unless specifically excepted or unless listed in
8another schedule, any material, compound, mixture, or
9preparation which contains any quantity of the following
10substances having a stimulant effect on the central nervous
11system, including its salts, isomers, and salts of isomers:
12        (1) Fenethylline;
13        (2) N-ethylamphetamine;
14        (3) Aminorex (some other names:
15    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
16    4-5-dihydro-5-phenyl-2-oxazolamine) and its
17    salts, optical isomers, and salts of optical isomers;
18        (4) Methcathinone (some other names:
19    2-methylamino-1-phenylpropan-1-one;
20    Ephedrone; 2-(methylamino)-propiophenone;
21    alpha-(methylamino)propiophenone; N-methylcathinone;
22    methycathinone; Monomethylpropion; UR 1431) and its
23    salts, optical isomers, and salts of optical isomers;
24        (5) Cathinone (some trade or other names:
25    2-aminopropiophenone; alpha-aminopropiophenone;
26    2-amino-1-phenyl-propanone; norephedrone);

 

 

SB1129 Enrolled- 42 -LRB099 05307 MRW 25342 b

1        (6) N,N-dimethylamphetamine (also known as:
2    N,N-alpha-trimethyl-benzeneethanamine;
3    N,N-alpha-trimethylphenethylamine);
4        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
5    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
6        (8) 3,4-Methylenedioxypyrovalerone (MDPV).
7    (g) Temporary listing of substances subject to emergency
8scheduling. Any material, compound, mixture, or preparation
9that contains any quantity of the following substances:
10        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
11    (benzylfentanyl), its optical isomers, isomers, salts,
12    and salts of isomers;
13        (2) N-[1(2-thienyl)
14   methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
15   its optical isomers, salts, and salts of isomers.
16    (h) Synthetic cathinones. Unless specifically excepted,
17any chemical compound not including bupropion, structurally
18derived from 2-aminopropan-1-one by substitution at the
191-position with either phenyl, naphthyl, or thiophene ring
20systems, whether or not the compound is further modified in one
21or more of the following ways:
22        (1) by substitution in the ring system to 
23    any extent with alkyl, alkylenedioxy, alkoxy, 
24    haloalkyl, hydroxyl, or halide substituents, whether 
25    or not further substituted in the ring system 
26    by one or more other univalent substituents. 

 

 

SB1129 Enrolled- 43 -LRB099 05307 MRW 25342 b

1    Examples of this class include, but are not 
2    limited to, 3,4-Methylenedioxycathinone 
3    (bk-MDA); 
4        (2) by substitution at the 3-position 
5    with an acyclic alkyl substituent. Examples of 
6    this class include, but are not limited to, 
7    2-methylamino-1-phenylbutan-1-one 
8    (buphedrone); or 
9        (3) by substitution at the 2-amino nitrogen 
10    atom with alkyl, dialkyl, benzyl, or methoxybenzyl 
11    groups, or by inclusion of the 2-amino nitrogen atom 
12    in a cyclic structure. Examples of this class include, 
13    but are not limited to, Dimethylcathinone, Ethcathinone, 
14    and a-Pyrrolidinopropiophenone (a-PPP). 
15(Source: P.A. 97-192, eff. 7-22-11; 97-193, eff. 1-1-12;
1697-194, eff. 7-22-11; 97-334, eff. 1-1-12; 97-813, eff.
177-13-12; 97-872, eff. 7-31-12; 98-987, eff. 1-1-15.)
 
18    (720 ILCS 570/401)  (from Ch. 56 1/2, par. 1401)
19    Sec. 401. Except as authorized by this Act, it is unlawful
20for any person knowingly to manufacture or deliver, or possess
21with intent to manufacture or deliver, a controlled substance
22other than methamphetamine, a counterfeit substance, or a
23controlled substance analog. A violation of this Act with
24respect to each of the controlled substances listed herein
25constitutes a single and separate violation of this Act. For

 

 

SB1129 Enrolled- 44 -LRB099 05307 MRW 25342 b

1purposes of this Section, "controlled substance analog" or
2"analog" means a substance which is intended for human
3consumption, other than a controlled substance, that has a
4chemical structure substantially similar to that of a
5controlled substance in Schedule I or II, or that was
6specifically designed to produce an effect substantially
7similar to that of a controlled substance in Schedule I or II.
8Examples of chemical classes in which controlled substance
9analogs are found include, but are not limited to, the
10following: phenethylamines, N-substituted piperidines,
11morphinans, ecgonines, quinazolinones, substituted indoles,
12and arylcycloalkylamines. For purposes of this Act, a
13controlled substance analog shall be treated in the same manner
14as the controlled substance to which it is substantially
15similar.
16    (a) Any person who violates this Section with respect to
17the following amounts of controlled or counterfeit substances
18or controlled substance analogs, notwithstanding any of the
19provisions of subsections (c), (d), (e), (f), (g) or (h) to the
20contrary, is guilty of a Class X felony and shall be sentenced
21to a term of imprisonment as provided in this subsection (a)
22and fined as provided in subsection (b):
23        (1) (A) not less than 6 years and not more than 30
24        years with respect to 15 grams or more but less than
25        100 grams of a substance containing heroin, or an
26        analog thereof;

 

 

SB1129 Enrolled- 45 -LRB099 05307 MRW 25342 b

1            (B) not less than 9 years and not more than 40
2        years with respect to 100 grams or more but less than
3        400 grams of a substance containing heroin, or an
4        analog thereof;
5            (C) not less than 12 years and not more than 50
6        years with respect to 400 grams or more but less than
7        900 grams of a substance containing heroin, or an
8        analog thereof;
9            (D) not less than 15 years and not more than 60
10        years with respect to 900 grams or more of any
11        substance containing heroin, or an analog thereof;
12        (1.5) (A) not less than 6 years and not more than 30
13        years with respect to 15 grams or more but less than
14        100 grams of a substance containing fentanyl, or an
15        analog thereof;
16            (B) not less than 9 years and not more than 40
17        years with respect to 100 grams or more but less than
18        400 grams of a substance containing fentanyl, or an
19        analog thereof;
20            (C) not less than 12 years and not more than 50
21        years with respect to 400 grams or more but less than
22        900 grams of a substance containing fentanyl, or an
23        analog thereof;
24            (D) not less than 15 years and not more than 60
25        years with respect to 900 grams or more of a substance
26        containing fentanyl, or an analog thereof;

 

 

SB1129 Enrolled- 46 -LRB099 05307 MRW 25342 b

1        (2) (A) not less than 6 years and not more than 30
2        years with respect to 15 grams or more but less than
3        100 grams of a substance containing cocaine, or an
4        analog thereof;
5            (B) not less than 9 years and not more than 40
6        years with respect to 100 grams or more but less than
7        400 grams of a substance containing cocaine, or an
8        analog thereof;
9            (C) not less than 12 years and not more than 50
10        years with respect to 400 grams or more but less than
11        900 grams of a substance containing cocaine, or an
12        analog thereof;
13            (D) not less than 15 years and not more than 60
14        years with respect to 900 grams or more of any
15        substance containing cocaine, or an analog thereof;
16        (3) (A) not less than 6 years and not more than 30
17        years with respect to 15 grams or more but less than
18        100 grams of a substance containing morphine, or an
19        analog thereof;
20            (B) not less than 9 years and not more than 40
21        years with respect to 100 grams or more but less than
22        400 grams of a substance containing morphine, or an
23        analog thereof;
24            (C) not less than 12 years and not more than 50
25        years with respect to 400 grams or more but less than
26        900 grams of a substance containing morphine, or an

 

 

SB1129 Enrolled- 47 -LRB099 05307 MRW 25342 b

1        analog thereof;
2            (D) not less than 15 years and not more than 60
3        years with respect to 900 grams or more of a substance
4        containing morphine, or an analog thereof;
5        (4) 200 grams or more of any substance containing
6    peyote, or an analog thereof;
7        (5) 200 grams or more of any substance containing a
8    derivative of barbituric acid or any of the salts of a
9    derivative of barbituric acid, or an analog thereof;
10        (6) 200 grams or more of any substance containing
11    amphetamine or any salt of an optical isomer of
12    amphetamine, or an analog thereof;
13        (6.5) (blank);
14        (6.6) (blank);
15        (7) (A) not less than 6 years and not more than 30
16        years with respect to: (i) 15 grams or more but less
17        than 100 grams of a substance containing lysergic acid
18        diethylamide (LSD), or an analog thereof, or (ii) 15 or
19        more objects or 15 or more segregated parts of an
20        object or objects but less than 200 objects or 200
21        segregated parts of an object or objects containing in
22        them or having upon them any amounts of any substance
23        containing lysergic acid diethylamide (LSD), or an
24        analog thereof;
25            (B) not less than 9 years and not more than 40
26        years with respect to: (i) 100 grams or more but less

 

 

SB1129 Enrolled- 48 -LRB099 05307 MRW 25342 b

1        than 400 grams of a substance containing lysergic acid
2        diethylamide (LSD), or an analog thereof, or (ii) 200
3        or more objects or 200 or more segregated parts of an
4        object or objects but less than 600 objects or less
5        than 600 segregated parts of an object or objects
6        containing in them or having upon them any amount of
7        any substance containing lysergic acid diethylamide
8        (LSD), or an analog thereof;
9            (C) not less than 12 years and not more than 50
10        years with respect to: (i) 400 grams or more but less
11        than 900 grams of a substance containing lysergic acid
12        diethylamide (LSD), or an analog thereof, or (ii) 600
13        or more objects or 600 or more segregated parts of an
14        object or objects but less than 1500 objects or 1500
15        segregated parts of an object or objects containing in
16        them or having upon them any amount of any substance
17        containing lysergic acid diethylamide (LSD), or an
18        analog thereof;
19            (D) not less than 15 years and not more than 60
20        years with respect to: (i) 900 grams or more of any
21        substance containing lysergic acid diethylamide (LSD),
22        or an analog thereof, or (ii) 1500 or more objects or
23        1500 or more segregated parts of an object or objects
24        containing in them or having upon them any amount of a
25        substance containing lysergic acid diethylamide (LSD),
26        or an analog thereof;

 

 

SB1129 Enrolled- 49 -LRB099 05307 MRW 25342 b

1        (7.5) (A) not less than 6 years and not more than 30
2        years with respect to: (i) 15 grams or more but less
3        than 100 grams of a substance listed in paragraph (1),
4        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
5        (21), (25), or (26) of subsection (d) of Section 204,
6        or an analog or derivative thereof, or (ii) 15 or more
7        pills, tablets, caplets, capsules, or objects but less
8        than 200 pills, tablets, caplets, capsules, or objects
9        containing in them or having upon them any amounts of
10        any substance listed in paragraph (1), (2), (2.1),
11        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
12        (26) of subsection (d) of Section 204, or an analog or
13        derivative thereof;
14            (B) not less than 9 years and not more than 40
15        years with respect to: (i) 100 grams or more but less
16        than 400 grams of a substance listed in paragraph (1),
17        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
18        (21), (25), or (26) of subsection (d) of Section 204,
19        or an analog or derivative thereof, or (ii) 200 or more
20        pills, tablets, caplets, capsules, or objects but less
21        than 600 pills, tablets, caplets, capsules, or objects
22        containing in them or having upon them any amount of
23        any substance listed in paragraph (1), (2), (2.1),
24        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
25        (26) of subsection (d) of Section 204, or an analog or
26        derivative thereof;

 

 

SB1129 Enrolled- 50 -LRB099 05307 MRW 25342 b

1            (C) not less than 12 years and not more than 50
2        years with respect to: (i) 400 grams or more but less
3        than 900 grams of a substance listed in paragraph (1),
4        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
5        (21), (25), or (26) of subsection (d) of Section 204,
6        or an analog or derivative thereof, or (ii) 600 or more
7        pills, tablets, caplets, capsules, or objects but less
8        than 1,500 pills, tablets, caplets, capsules, or
9        objects containing in them or having upon them any
10        amount of any substance listed in paragraph (1), (2),
11        (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21),
12        (25), or (26) of subsection (d) of Section 204, or an
13        analog or derivative thereof;
14            (D) not less than 15 years and not more than 60
15        years with respect to: (i) 900 grams or more of any
16        substance listed in paragraph (1), (2), (2.1), (2.2),
17        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
18        subsection (d) of Section 204, or an analog or
19        derivative thereof, or (ii) 1,500 or more pills,
20        tablets, caplets, capsules, or objects containing in
21        them or having upon them any amount of a substance
22        listed in paragraph (1), (2), (2.1), (2.2), (3),
23        (14.1), (19), (20), (20.1), (21), (25), or (26) of
24        subsection (d) of Section 204, or an analog or
25        derivative thereof;
26        (8) 30 grams or more of any substance containing

 

 

SB1129 Enrolled- 51 -LRB099 05307 MRW 25342 b

1    pentazocine or any of the salts, isomers and salts of
2    isomers of pentazocine, or an analog thereof;
3        (9) 30 grams or more of any substance containing
4    methaqualone or any of the salts, isomers and salts of
5    isomers of methaqualone, or an analog thereof;
6        (10) 30 grams or more of any substance containing
7    phencyclidine or any of the salts, isomers and salts of
8    isomers of phencyclidine (PCP), or an analog thereof;
9        (10.5) 30 grams or more of any substance containing
10    ketamine or any of the salts, isomers and salts of isomers
11    of ketamine, or an analog thereof;
12        (10.6) 100 grams or more of any substance containing
13    hydrocodone, or any of the salts, isomers and salts of
14    isomers of hydrocodone, or an analog thereof;
15        (10.7) 100 grams or more of any substance containing
16    dihydrocodeinone, or any of the salts, isomers and salts of
17    isomers of dihydrocodeinone, or an analog thereof;
18        (10.8) 100 grams or more of any substance containing
19    dihydrocodeine, or any of the salts, isomers and salts of
20    isomers of dihydrocodeine, or an analog thereof;
21        (10.9) 100 grams or more of any substance containing
22    oxycodone, or any of the salts, isomers and salts of
23    isomers of oxycodone, or an analog thereof;
24        (11) 200 grams or more of any substance containing any
25    other controlled substance classified in Schedules I or II,
26    or an analog thereof, which is not otherwise included in

 

 

SB1129 Enrolled- 52 -LRB099 05307 MRW 25342 b

1    this subsection.
2    (b) Any person sentenced with respect to violations of
3paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
4involving 100 grams or more of the controlled substance named
5therein, may in addition to the penalties provided therein, be
6fined an amount not more than $500,000 or the full street value
7of the controlled or counterfeit substance or controlled
8substance analog, whichever is greater. The term "street value"
9shall have the meaning ascribed in Section 110-5 of the Code of
10Criminal Procedure of 1963. Any person sentenced with respect
11to any other provision of subsection (a), may in addition to
12the penalties provided therein, be fined an amount not to
13exceed $500,000.
14    (b-1) Excluding violations of this Act when the controlled
15substance is fentanyl, any person sentenced to a term of
16imprisonment with respect to violations of Section 401, 401.1,
17405, 405.1, 405.2, or 407, when the substance containing the
18controlled substance contains any amount of fentanyl, 3 years
19shall be added to the term of imprisonment imposed by the
20court, and the maximum sentence for the offense shall be
21increased by 3 years.
22    (c) Any person who violates this Section with regard to the
23following amounts of controlled or counterfeit substances or
24controlled substance analogs, notwithstanding any of the
25provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
26to the contrary, is guilty of a Class 1 felony. The fine for

 

 

SB1129 Enrolled- 53 -LRB099 05307 MRW 25342 b

1violation of this subsection (c) shall not be more than
2$250,000:
3        (1) 1 gram or more but less than 15 grams of any
4    substance containing heroin, or an analog thereof;
5        (1.5) 1 gram or more but less than 15 grams of any
6    substance containing fentanyl, or an analog thereof;
7        (2) 1 gram or more but less than 15 grams of any
8    substance containing cocaine, or an analog thereof;
9        (3) 10 grams or more but less than 15 grams of any
10    substance containing morphine, or an analog thereof;
11        (4) 50 grams or more but less than 200 grams of any
12    substance containing peyote, or an analog thereof;
13        (5) 50 grams or more but less than 200 grams of any
14    substance containing a derivative of barbituric acid or any
15    of the salts of a derivative of barbituric acid, or an
16    analog thereof;
17        (6) 50 grams or more but less than 200 grams of any
18    substance containing amphetamine or any salt of an optical
19    isomer of amphetamine, or an analog thereof;
20        (6.5) (blank);
21        (7) (i) 5 grams or more but less than 15 grams of any
22    substance containing lysergic acid diethylamide (LSD), or
23    an analog thereof, or (ii) more than 10 objects or more
24    than 10 segregated parts of an object or objects but less
25    than 15 objects or less than 15 segregated parts of an
26    object containing in them or having upon them any amount of

 

 

SB1129 Enrolled- 54 -LRB099 05307 MRW 25342 b

1    any substance containing lysergic acid diethylamide (LSD),
2    or an analog thereof;
3        (7.5) (i) 5 grams or more but less than 15 grams of any
4    substance listed in paragraph (1), (2), (2.1), (2.2), (3),
5    (14.1), (19), (20), (20.1), (21), (25), or (26) of
6    subsection (d) of Section 204, or an analog or derivative
7    thereof, or (ii) more than 10 pills, tablets, caplets,
8    capsules, or objects but less than 15 pills, tablets,
9    caplets, capsules, or objects containing in them or having
10    upon them any amount of any substance listed in paragraph
11    (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12    (21), (25), or (26) of subsection (d) of Section 204, or an
13    analog or derivative thereof;
14        (8) 10 grams or more but less than 30 grams of any
15    substance containing pentazocine or any of the salts,
16    isomers and salts of isomers of pentazocine, or an analog
17    thereof;
18        (9) 10 grams or more but less than 30 grams of any
19    substance containing methaqualone or any of the salts,
20    isomers and salts of isomers of methaqualone, or an analog
21    thereof;
22        (10) 10 grams or more but less than 30 grams of any
23    substance containing phencyclidine or any of the salts,
24    isomers and salts of isomers of phencyclidine (PCP), or an
25    analog thereof;
26        (10.5) 10 grams or more but less than 30 grams of any

 

 

SB1129 Enrolled- 55 -LRB099 05307 MRW 25342 b

1    substance containing ketamine or any of the salts, isomers
2    and salts of isomers of ketamine, or an analog thereof;
3        (10.6) 50 grams or more but less than 100 grams of any
4    substance containing hydrocodone, or any of the salts,
5    isomers and salts of isomers of hydrocodone, or an analog
6    thereof;
7        (10.7) 50 grams or more but less than 100 grams of any
8    substance containing dihydrocodeinone, or any of the
9    salts, isomers and salts of isomers of dihydrocodeinone, or
10    an analog thereof;
11        (10.8) 50 grams or more but less than 100 grams of any
12    substance containing dihydrocodeine, or any of the salts,
13    isomers and salts of isomers of dihydrocodeine, or an
14    analog thereof;
15        (10.9) 50 grams or more but less than 100 grams of any
16    substance containing oxycodone, or any of the salts,
17    isomers and salts of isomers of oxycodone, or an analog
18    thereof;
19        (11) 50 grams or more but less than 200 grams of any
20    substance containing a substance classified in Schedules I
21    or II, or an analog thereof, which is not otherwise
22    included in this subsection.
23    (c-5) (Blank).
24    (d) Any person who violates this Section with regard to any
25other amount of a controlled or counterfeit substance
26containing dihydrocodeinone or dihydrocodeine or classified in

 

 

SB1129 Enrolled- 56 -LRB099 05307 MRW 25342 b

1Schedules I or II, or an analog thereof, which is (i) a
2narcotic drug, (ii) lysergic acid diethylamide (LSD) or an
3analog thereof, (iii) any substance containing amphetamine or
4fentanyl or any salt or optical isomer of amphetamine or
5fentanyl, or an analog thereof, or (iv) any substance
6containing N-Benzylpiperazine (BZP) or any salt or optical
7isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
8guilty of a Class 2 felony. The fine for violation of this
9subsection (d) shall not be more than $200,000.
10    (d-5) (Blank).
11    (e) Any person who violates this Section with regard to any
12other amount of a controlled substance other than
13methamphetamine or counterfeit substance classified in
14Schedule I or II, or an analog thereof, which substance is not
15included under subsection (d) of this Section, is guilty of a
16Class 3 felony. The fine for violation of this subsection (e)
17shall not be more than $150,000.
18    (f) Any person who violates this Section with regard to any
19other amount of a controlled or counterfeit substance
20classified in Schedule III is guilty of a Class 3 felony. The
21fine for violation of this subsection (f) shall not be more
22than $125,000.
23    (g) Any person who violates this Section with regard to any
24other amount of a controlled or counterfeit substance
25classified in Schedule IV is guilty of a Class 3 felony. The
26fine for violation of this subsection (g) shall not be more

 

 

SB1129 Enrolled- 57 -LRB099 05307 MRW 25342 b

1than $100,000.
2    (h) Any person who violates this Section with regard to any
3other amount of a controlled or counterfeit substance
4classified in Schedule V is guilty of a Class 3 felony. The
5fine for violation of this subsection (h) shall not be more
6than $75,000.
7    (i) This Section does not apply to the manufacture,
8possession or distribution of a substance in conformance with
9the provisions of an approved new drug application or an
10exemption for investigational use within the meaning of Section
11505 of the Federal Food, Drug and Cosmetic Act.
12    (j) (Blank).
13(Source: P.A. 96-347, eff. 1-1-10; 97-997, eff. 1-1-13.)
 
14    (720 ILCS 570/402)  (from Ch. 56 1/2, par. 1402)
15    Sec. 402. Except as otherwise authorized by this Act, it is
16unlawful for any person knowingly to possess a controlled or
17counterfeit substance or controlled substance analog. A
18violation of this Act with respect to each of the controlled
19substances listed herein constitutes a single and separate
20violation of this Act. For purposes of this Section,
21"controlled substance analog" or "analog" means a substance
22which is intended for human consumption, other than a
23controlled substance, that has a chemical structure
24substantially similar to that of a controlled substance in
25Schedule I or II, or that was specifically designed to produce

 

 

SB1129 Enrolled- 58 -LRB099 05307 MRW 25342 b

1an effect substantially similar to that of a controlled
2substance in Schedule I or II. Examples of chemical classes in
3which controlled substance analogs are found include, but are
4not limited to, the following: phenethylamines, N-substituted
5piperidines, morphinans, ecgonines, quinazolinones,
6substituted indoles, and arylcycloalkylamines. For purposes of
7this Act, a controlled substance analog shall be treated in the
8same manner as the controlled substance to which it is
9substantially similar.
10    (a) Any person who violates this Section with respect to
11the following controlled or counterfeit substances and
12amounts, notwithstanding any of the provisions of subsections
13(c) and (d) to the contrary, is guilty of a Class 1 felony and
14shall, if sentenced to a term of imprisonment, be sentenced as
15provided in this subsection (a) and fined as provided in
16subsection (b):
17        (1) (A) not less than 4 years and not more than 15
18        years with respect to 15 grams or more but less than
19        100 grams of a substance containing heroin;
20            (B) not less than 6 years and not more than 30
21        years with respect to 100 grams or more but less than
22        400 grams of a substance containing heroin;
23            (C) not less than 8 years and not more than 40
24        years with respect to 400 grams or more but less than
25        900 grams of any substance containing heroin;
26            (D) not less than 10 years and not more than 50

 

 

SB1129 Enrolled- 59 -LRB099 05307 MRW 25342 b

1        years with respect to 900 grams or more of any
2        substance containing heroin;
3        (2) (A) not less than 4 years and not more than 15
4        years with respect to 15 grams or more but less than
5        100 grams of any substance containing cocaine;
6            (B) not less than 6 years and not more than 30
7        years with respect to 100 grams or more but less than
8        400 grams of any substance containing cocaine;
9            (C) not less than 8 years and not more than 40
10        years with respect to 400 grams or more but less than
11        900 grams of any substance containing cocaine;
12            (D) not less than 10 years and not more than 50
13        years with respect to 900 grams or more of any
14        substance containing cocaine;
15        (3) (A) not less than 4 years and not more than 15
16        years with respect to 15 grams or more but less than
17        100 grams of any substance containing morphine;
18            (B) not less than 6 years and not more than 30
19        years with respect to 100 grams or more but less than
20        400 grams of any substance containing morphine;
21            (C) not less than 6 years and not more than 40
22        years with respect to 400 grams or more but less than
23        900 grams of any substance containing morphine;
24            (D) not less than 10 years and not more than 50
25        years with respect to 900 grams or more of any
26        substance containing morphine;

 

 

SB1129 Enrolled- 60 -LRB099 05307 MRW 25342 b

1        (4) 200 grams or more of any substance containing
2    peyote;
3        (5) 200 grams or more of any substance containing a
4    derivative of barbituric acid or any of the salts of a
5    derivative of barbituric acid;
6        (6) 200 grams or more of any substance containing
7    amphetamine or any salt of an optical isomer of
8    amphetamine;
9        (6.5) (blank);
10        (7) (A) not less than 4 years and not more than 15
11        years with respect to: (i) 15 grams or more but less
12        than 100 grams of any substance containing lysergic
13        acid diethylamide (LSD), or an analog thereof, or (ii)
14        15 or more objects or 15 or more segregated parts of an
15        object or objects but less than 200 objects or 200
16        segregated parts of an object or objects containing in
17        them or having upon them any amount of any substance
18        containing lysergic acid diethylamide (LSD), or an
19        analog thereof;
20            (B) not less than 6 years and not more than 30
21        years with respect to: (i) 100 grams or more but less
22        than 400 grams of any substance containing lysergic
23        acid diethylamide (LSD), or an analog thereof, or (ii)
24        200 or more objects or 200 or more segregated parts of
25        an object or objects but less than 600 objects or less
26        than 600 segregated parts of an object or objects

 

 

SB1129 Enrolled- 61 -LRB099 05307 MRW 25342 b

1        containing in them or having upon them any amount of
2        any substance containing lysergic acid diethylamide
3        (LSD), or an analog thereof;
4            (C) not less than 8 years and not more than 40
5        years with respect to: (i) 400 grams or more but less
6        than 900 grams of any substance containing lysergic
7        acid diethylamide (LSD), or an analog thereof, or (ii)
8        600 or more objects or 600 or more segregated parts of
9        an object or objects but less than 1500 objects or 1500
10        segregated parts of an object or objects containing in
11        them or having upon them any amount of any substance
12        containing lysergic acid diethylamide (LSD), or an
13        analog thereof;
14            (D) not less than 10 years and not more than 50
15        years with respect to: (i) 900 grams or more of any
16        substance containing lysergic acid diethylamide (LSD),
17        or an analog thereof, or (ii) 1500 or more objects or
18        1500 or more segregated parts of an object or objects
19        containing in them or having upon them any amount of a
20        substance containing lysergic acid diethylamide (LSD),
21        or an analog thereof;
22        (7.5) (A) not less than 4 years and not more than 15
23        years with respect to: (i) 15 grams or more but less
24        than 100 grams of any substance listed in paragraph
25        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
26        (20.1), (21), (25), or (26) of subsection (d) of

 

 

SB1129 Enrolled- 62 -LRB099 05307 MRW 25342 b

1        Section 204, or an analog or derivative thereof, or
2        (ii) 15 or more pills, tablets, caplets, capsules, or
3        objects but less than 200 pills, tablets, caplets,
4        capsules, or objects containing in them or having upon
5        them any amount of any substance listed in paragraph
6        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
7        (20.1), (21), (25), or (26) of subsection (d) of
8        Section 204, or an analog or derivative thereof;
9            (B) not less than 6 years and not more than 30
10        years with respect to: (i) 100 grams or more but less
11        than 400 grams of any substance listed in paragraph
12        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
13        (20.1), (21), (25), or (26) of subsection (d) of
14        Section 204, or an analog or derivative thereof, or
15        (ii) 200 or more pills, tablets, caplets, capsules, or
16        objects but less than 600 pills, tablets, caplets,
17        capsules, or objects containing in them or having upon
18        them any amount of any substance listed in paragraph
19        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
20        (20.1), (21), (25), or (26) of subsection (d) of
21        Section 204, or an analog or derivative thereof;
22            (C) not less than 8 years and not more than 40
23        years with respect to: (i) 400 grams or more but less
24        than 900 grams of any substance listed in paragraph
25        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
26        (20.1), (21), (25), or (26) of subsection (d) of

 

 

SB1129 Enrolled- 63 -LRB099 05307 MRW 25342 b

1        Section 204, or an analog or derivative thereof, or
2        (ii) 600 or more pills, tablets, caplets, capsules, or
3        objects but less than 1,500 pills, tablets, caplets,
4        capsules, or objects containing in them or having upon
5        them any amount of any substance listed in paragraph
6        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
7        (20.1), (21), (25), or (26) of subsection (d) of
8        Section 204, or an analog or derivative thereof;
9            (D) not less than 10 years and not more than 50
10        years with respect to: (i) 900 grams or more of any
11        substance listed in paragraph (1), (2), (2.1), (2.2),
12        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
13        subsection (d) of Section 204, or an analog or
14        derivative thereof, or (ii) 1,500 or more pills,
15        tablets, caplets, capsules, or objects containing in
16        them or having upon them any amount of a substance
17        listed in paragraph (1), (2), (2.1), (2.2), (3),
18        (14.1), (19), (20), (20.1), (21), (25), or (26) of
19        subsection (d) of Section 204, or an analog or
20        derivative thereof;
21        (8) 30 grams or more of any substance containing
22    pentazocine or any of the salts, isomers and salts of
23    isomers of pentazocine, or an analog thereof;
24        (9) 30 grams or more of any substance containing
25    methaqualone or any of the salts, isomers and salts of
26    isomers of methaqualone;

 

 

SB1129 Enrolled- 64 -LRB099 05307 MRW 25342 b

1        (10) 30 grams or more of any substance containing
2    phencyclidine or any of the salts, isomers and salts of
3    isomers of phencyclidine (PCP);
4        (10.5) 30 grams or more of any substance containing
5    ketamine or any of the salts, isomers and salts of isomers
6    of ketamine;
7        (11) 200 grams or more of any substance containing any
8    substance classified as a narcotic drug in Schedules I or
9    II, or an analog thereof, which is not otherwise included
10    in this subsection.
11    (b) Any person sentenced with respect to violations of
12paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
13involving 100 grams or more of the controlled substance named
14therein, may in addition to the penalties provided therein, be
15fined an amount not to exceed $200,000 or the full street value
16of the controlled or counterfeit substances, whichever is
17greater. The term "street value" shall have the meaning
18ascribed in Section 110-5 of the Code of Criminal Procedure of
191963. Any person sentenced with respect to any other provision
20of subsection (a), may in addition to the penalties provided
21therein, be fined an amount not to exceed $200,000.
22    (c) Any person who violates this Section with regard to an
23amount of a controlled substance other than methamphetamine or
24counterfeit substance not set forth in subsection (a) or (d) is
25guilty of a Class 4 felony. The fine for a violation punishable
26under this subsection (c) shall not be more than $25,000.

 

 

SB1129 Enrolled- 65 -LRB099 05307 MRW 25342 b

1    (d) Any person who violates this Section with regard to any
2amount of anabolic steroid is guilty of a Class C misdemeanor
3for the first offense and a Class B misdemeanor for a
4subsequent offense committed within 2 years of a prior
5conviction.
6(Source: P.A. 95-331, eff. 8-21-07; 96-347, eff. 1-1-10.)